IIM
BCRX icon

INTECH Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

INTECH Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$478K Sell
47,763
-2,315
-5% -$20.9K ﹤0.01% 1366
2026
Q1 		$477K Sell
50,078
-29,340
-37% -$228K ﹤0.01% 1350
2025
Q4 		$619K Sell
79,418
-21,818
-22% -$158K 0.01% 1390
2025
Q3 		$768K Sell
101,236
-22,936
-18% -$191K 0.01% 1337
2025
Q2 		$1.11M Hold
124,172
– – 0.01% 1135
2025
Q1 		$931K Buy
124,172
+26,379
+27% +$213K 0.01% 1237
2024
Q4 		$735K Buy
97,793
+43,556
+80% +$331K 0.01% 1335
2024
Q3 		$412K Buy
+54,237
New +$412K ﹤0.01% 1332

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

INTECH Investment Management's BCRX Position: Q2 2026 in Review

INTECH Investment Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 4.6% in Q2 2026, selling an estimated $20.9K and leaving 47,763 shares worth $478K. The position accounts for ﹤0.01% of the portfolio, ranked #1366.

INTECH Investment Management first reported a position in BCRX in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.11M in Q2 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • INTECH Investment Management held 47,763 shares of BioCryst Pharmaceuticals worth $478K as of Q2 2026.
  • INTECH Investment Management sold 2,315 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $20.9K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1366 holding.
  • INTECH Investment Management first reported a position in BioCryst Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • INTECH Investment Management's BioCryst Pharmaceuticals position peaked at $1.11M in Q2 2025.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.